EA
VRTX icon

Emerald Acquisition’s Vertex Pharmaceuticals VRTX Stock Holding History

Emerald Acquisition’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$15M Sell
171,523
-8,441
-5% -$798K 0.03% 655
2016
Q2 		$15.5M Buy
+179,964
New +$15.6M 0.03% 697

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Emerald Acquisition's VRTX Position: Q3 2016 in Review

Emerald Acquisition reduced its Vertex Pharmaceuticals (VRTX) stake by 4.7% in Q3 2016, selling an estimated $798K and leaving 171,523 shares worth $15M. The position accounts for 0.03% of the portfolio, ranked #655.

Emerald Acquisition first reported a position in VRTX in Q2 2016 and has held it in 2 quarters since. The position peaked at $15.5M in Q2 2016. 489 funds tracked by Wall St. Rank hold VRTX as of Q3 2016.

  • Emerald Acquisition held 171,523 shares of Vertex Pharmaceuticals worth $15M as of Q3 2016.
  • Emerald Acquisition sold 8,441 Vertex Pharmaceuticals shares in Q3 2016, an estimated $798K.
  • Vertex Pharmaceuticals made up 0.03% of Emerald Acquisition's portfolio in Q3 2016, its #655 holding.
  • Emerald Acquisition first reported a position in Vertex Pharmaceuticals in Q2 2016 and has held it in 2 quarters since.
  • Emerald Acquisition's Vertex Pharmaceuticals position peaked at $15.5M in Q2 2016.
  • 489 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.